Publications by authors named "Raymond Meng"

Claim this Profile
A
Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T cells.
Xiangnan Guan, Ruozhen Hu, Yoonha Choi, Shyam Srivats, Barzin Y Nabet, Raymond Meng

Nature· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T cells.
Xiangnan Guan, Ruozhen Hu, Yoonha Choi, Shyam Srivats, Barzin Y Nabet, Raymond Meng

Nature· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T cells.
Xiangnan Guan, Ruozhen Hu, Yoonha Choi, Shyam Srivats, Barzin Y Nabet, Raymond Meng

Nature· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T cells.
Xiangnan Guan, Ruozhen Hu, Yoonha Choi, Shyam Srivats, Barzin Y Nabet, Raymond Meng

Nature· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
Charles M Rudin, Stephen V Liu, Ross A Soo, Shun Lu, Min Hee Hong, Raymond Meng

J Clin Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
Tae Won Kim, Philippe L Bedard, Patricia LoRusso, Michael S Gordon, Johanna Bendell, Raymond Meng

JAMA Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Byoung Chul Cho, Delvys Rodriguez Abreu, Maen Hussein, Manuel Cobo, Anjan J Patel, Raymond Meng

Lancet Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib.
Vikram Malhi, Nageshwar Budha, Rucha Sane, Jian Huang, Bianca Liederer, Raymond Meng

Cancer Chemother Pharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Geoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, Luna Musib, Yibing Yan, Raymond D Meng

Invest New Drugs· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.
Shahneen Sandhu, Catriona M McNeil, Patricia LoRusso, Manish R Patel, Omar Kabbarah, Raymond Meng

Invest New Drugs· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
Cristina Saura, Desamparados Roda, Susana Roselló, Mafalda Oliveira, Teresa Macarulla, Raymond D Meng

Cancer Discov· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients.
Andrew S Epstein, Angelo E Volandes, Ling Y Chen, Kristen A Gary, Yuelin Li, Raymond D Meng

J Palliat Med· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.
Raymond D Meng, Christopher C Shelton, Yue-Ming Li, Li-Xuan Qin, Daniel Notterman

Cancer Res· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis